Active Filter(s):
Details:
KIT2014, a novel, cell-permeable peptide that works to modulate cAMP levels inside cells, demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflammation.
Lead Product(s): KIT2014
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KIT2014
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Lead Product(s): KIT2014
Therapeutic Area: Genetic Disease Product Name: KIT2014
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Claris Ventures
Deal Size: $18.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 16, 2022